Replies to post #25187 on Cytodyn Inc (CYDY)

[BlackDoggie]

Interesting question for sure. I’d also like to hear input from anyone with significant experience in this realm. How would it be impacted by having parents for several and varied indications? And how would marketing protections under ODD for GvHD impact the protection for HIV? I would have liked to hear some talk about that on the call, but it probably wasn’t the most pressing issue when we hadn’t heard from management in nine months... Maybe on the next call, if we can’t get it well sorted before then.

Good question, WB.

[finesand]

wooden- re patents (Pro 140 and Pestell!)

After BLA approval CYDY would have a red book (?) exclusivity,
see HC WainWright 2016 analysis p10:

CytoDyn has 10 issued and six pending U.S. patents. Without additional patent term extension,
patent protection relating to the PRO 140 antibody starts to expire in 2023, certain methods of
using PRO 140 start to expire in 2026, and certain formulations comprising PRO 140 start to
expire in 2031. We note that as a biologic drug, PRO 140 would secure 12-year market
exclusivity if approved, based on the current legislative framework surrounding biosimilar drugs.

Regarding CEO + Pestell's answer regarding Pestell's patent,
CEO simply said 'correct' and Pestell confirmed he took back the patent from ProstateGene by agreeing and then mumbled something about synergies. Around 45:30 in CC.
Question here is: Does this actually mean Pestell's patent(s) will be transferred in the deal?

Auto-Transcript

45:20 the the merger was mr. pastels so there
45:26 was one circulating question and our
45:28 community which was about the patent he
45:31 owns and the patent was moved from the
45:35 to be acquired company and back to mr.
45:41 pastels ownership so can we assume when
45:46 you acquire the company that you also
45:50 acquire the patent that the correct of
45:53 the way is 9 4 5 3 8 3 6 b2 correct
46:00 doctor comment on that yes the intention
46:07 is to create genuine arkad synergy by
46:12 the acquisition by cited in of these
46:17 patterns these issued patients providing
46:20 I think substantial leverage in that
46:22 marketplace thank you